Antimicrobial resistance (AMR) is one of the key global public health challenges of our time.
At least 700,000 people die each year due to AMR-related causes.5 Left unchecked, the annual
global death toll from AMR could reach ten million by 2050.6 The emergence of treatment-resistant
bacteria, viruses, parasites, and fungi threaten to make previously treatable infections
more difficult to treat or cure and pose new risks to the safety of existing medical procedures,
such as chemotherapy. There are also growing concerns that the COVID-19 pandemic may
exacerbate the threat of AMR due to increased or inappropriate antimicrobial use.7 In addition,
evidence suggests that the prevalence of hospital-acquired infections, including treatment-resistant
ones, also increased with the burden of COVID-19.8,9 In recent years, and in recognition
of the complexity of the challenge presented by AMR, efforts to tackle the emergence and
spread of AMR have been enhanced by governments, international organizations, the life
sciences industries, healthcare professionals, academics, not-for-profit organizations and civil

Sodipress vous remercie de renseigner votre email pour recevoir le document.
Envoyer le document
You May Also Like